The importance of individually customized treatment for CLL patients
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.
How can MRD and disease be assessed in routine practice?
Factors to consider in frontline and relapsed CLL before treatment
Advancements at ASH 2017 that are directly relevant to patients